A Study of NB003 in Patients With Advanced Malignancies
A Multicenter Phase 1, Open-Label Study of NB003 to Assess Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Malignancies
Sponsor: Ningbo Newbay Technology Development Co., Ltd
Listed as NCT04936178, this PHASE1 trial focuses on Advanced Solid Tumor and remains completed. Sponsored by Ningbo Newbay Technology Development Co., Ltd, it has been updated 12 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Sep 2025 — Jan 2026 [monthly]
Recruiting PHASE1
-
Jun 2025 — Sep 2025 [monthly]
Recruiting PHASE1
-
Mar 2025 — Jun 2025 [monthly]
Recruiting PHASE1
-
Sep 2024 — Mar 2025 [monthly]
Recruiting PHASE1
▶ Show 7 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
Jan 2024 — Jun 2024 [monthly]
Recruiting PHASE1
-
Oct 2023 — Jan 2024 [monthly]
Recruiting PHASE1
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE1
-
Mar 2022 — Sep 2023 [monthly]
Recruiting PHASE1
-
Sep 2021 — Mar 2022 [monthly]
Recruiting PHASE1
First recorded
Aug 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ningbo Newbay Technology Development Co., Ltd
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain , Beijing, China , Boston, United States , Changsha, China , Chengdu, China , Chongqing, China , Fuzhou, China , Guangzhou, China , Hangzhou, China , Harbin, China and 18 more locations